NCCN Guidelines for Multiple Myeloma Updated to Include Three Selinexor Regimens
The National Comprehensive Cancer Network’s updated Clinical Practice Guidelines in Oncology for multiple myeloma newly include 3 new selinexor-containing regimens.
All articles by Caroline Seydel
Sodium Bicarbonate Associated With Enhanced GVL Effect in AML Following Allo-HSCT
Investigators assessed sodium bicarbonate’s viability as a pharmacologic strategy in mouse models and humans with acute myeloid leukemia.
No Need for Radiotherapy in Hodgkin Lymphoma With Negative PET Scan
Even patients with bulky disease had no difference in survival after chemotherapy, provided their PET scan was negative.
First-Ever Prospective Trial in Pediatric RCC Reports Results
The prospective study showed that after 4 years, complete resection of the tumor for children with local lymph node involvement (no metastasis) delivered an overall survival rate of 91.4%.
Triple Therapy for CLL Shows Promise in Phase 2 Trial
Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.
A New Hope for IL-18 Therapy
Engineered cytokine evades the tumor’s defenses and boosts the production of stem-like polyfunctional T cells.
New Class of Drug Appears to Extend Survival in Patients With Triple-Refractory Multiple Myeloma
Oncopeptides will seek accelerated approval from the FDA after melflufen demonstrates a manageable safety profile.
Androgen Deprivation Therapy May Protect Against COVID-19 in Prostate Cancer
Androgen deprivation therapy showed a protective effect among prostate cancer patients in Veneto.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
CAR-NK Cells Make Their Debut in Hematologic Cancers
The new type of adoptive cell therapy showed a response in 8 of 11 patients with hematologic malignancies in a clinical study.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...